Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
METROGEL vs METRO I.V. IN PLASTIC CONTAINER
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Metronidazole, after intracellular reduction, forms cytotoxic metabolites that disrupt bacterial DNA and inhibit nucleic acid synthesis. It also has anti-inflammatory and immunomodulatory effects in rosacea.
Metronidazole exerts its antibacterial and antiprotozoal effects by entering the microbial cell and undergoing reduction by intracellular electron transport proteins, forming reactive metabolites that interact with DNA, causing strand breakage and inhibition of nucleic acid synthesis.
Topical treatment of inflammatory papules and pustules of rosacea,Treatment of bacterial vaginosis (off-label),Treatment of acne vulgaris (off-label)
Treatment of intra-abdominal infections (peritonitis, intra-abdominal abscess),Treatment of bacterial vaginosis,Treatment of trichomoniasis,Treatment of amebiasis (amebic dysentery and amebic liver abscess),Treatment of skin and skin structure infections (decubitus ulcers, infected wounds),Treatment of gynecologic infections (endometritis, tubo-ovarian abscess),Treatment of central nervous system infections (meningitis, brain abscess),Treatment of septicemia and endocarditis,Off-label: Perioperative prophylaxis for colorectal surgery,Off-label: Treatment of Helicobacter pylori infection (combined with other agents),Off-label: Crohn's disease (perianal fistulas)
Topical application of 1% gel: Apply a thin layer to affected area twice daily; intravaginal 0.75% gel: one applicatorful (5 g) once daily at bedtime.
IV: 500 mg every 6 h or 1 g every 12 h. For severe infections: 750 mg every 6 h. Max 4 g/day.
8-10 hours (terminal); increased to 20-30 hours in hepatic impairment.
8 hours (6-12 hours) in adults; prolonged in hepatic impairment
Hepatic via glucuronidation and oxidation; metabolites excreted renally.
Hepatic metabolism via oxidation and glucuronidation, primarily by CYP450 enzymes (CYP2A6, CYP3A4). The major metabolites are hydroxymetronidazole and metronidazole glucuronide.
Renal: 60-80% as unchanged drug; fecal: 6-15%; biliary: minor.
Renal (60-80% as unchanged drug), fecal (6-15%), biliary (small amount)
Less than 20%; albumin.
<20% bound to plasma proteins
0.25-0.85 L/kg; extensive tissue distribution including CSF.
0.25-0.85 L/kg; indicates wide distribution into tissues including CSF
Topical: minimal systemic absorption (2-4%); oral: 80-100%; intravenous: 100%.
100% intravenous
No dose adjustment required for topical or intravaginal use; systemic absorption is minimal.
Cr Cl 10-50 m L/min: 500 mg every 12 h. Cr Cl <10 m L/min: 500 mg every 24 h. Hemodialysis: dose after dialysis.
No dose adjustment required; use with caution in severe hepatic impairment due to potential for increased systemic exposure.
Child-Pugh A: no adjustment. Child-Pugh B or C: reduce dose by 50% (e.g., 500 mg every 12 h).
Topical 1% gel: apply twice daily for children ≥12 years; safety and efficacy for rosacea in children <12 not established.
Neonates (GA <34 wk): 7.5 mg/kg every 12 h; (GA ≥34 wk): 7.5 mg/kg every 8 h. Infants/children: 10 mg/kg every 6-8 h. Max 4 g/day.
No specific dose adjustment; use same dosing as adults; monitor for local adverse effects due to thinner skin.
Cr Cl 10-50 m L/min: 500 mg every 12 h. Cr Cl <10 m L/min: 500 mg every 24 h. Monitor for neurotoxicity.
No FDA black box warning.
Carcinogenicity: Metronidazole has been shown to be carcinogenic in mice and rats. Unnecessary use should be avoided.
Avoid unnecessary prolonged use; may cause peripheral neuropathy with chronic use; discontinue if neurological symptoms occur; photosensitivity reactions; avoid sun exposure.
May cause seizures and peripheral neuropathy; discontinue if neurologic symptoms occur.,Use caution in patients with central nervous system disorders.,Blood dyscrasias: Use with caution in patients with history of or current blood dyscrasias.,Hepatic impairment: Dose adjustment may be required.,Carcinogenicity: Avoid prolonged or unnecessary use.,Drug interactions: Potentiation of anticoagulant effect of warfarin; disulfiram-like reaction with alcohol.,Prolonged QT interval: Use with caution with QT-prolonging agents.,Superinfection: May cause overgrowth of Clostridioides difficile.
Hypersensitivity to metronidazole or any component of the formulation; concurrent disulfiram use; history of alcoholic beverage consumption during therapy.
Hypersensitivity to metronidazole or other nitroimidazole derivatives,First trimester of pregnancy (relative contraindication; use only if clearly needed),Breastfeeding (manufacturer recommends discontinuation of nursing or drug, but AAP considers compatible),Use with disulfiram (within 2 weeks of disulfiram administration),Use with alcohol or propylene glycol-containing products (due to disulfiram-like reaction)
No significant food interactions specific to topical metronidazole; however, systemic metronidazole has alcohol interaction (disulfiram-like reaction), so patients should avoid alcohol while using topical formulation? Although topical absorption is minimal, caution is advised. No specific dietary restrictions.
Avoid alcohol and any foods or beverages containing alcohol (e.g., beer, wine, liquor, some vinegars, certain desserts) for 48 hours after last dose. No other significant food interactions.
Metronidazole crosses the placenta. First trimester: avoid unless essential; second/third trimester: no increased risk of major malformations in large cohort studies; potential neurodevelopmental risks unclear.
Metronidazole crosses the placenta. In the first trimester, data are conflicting but meta-analyses show no significant increase in major malformations; however, some studies suggest a possible small risk of cleft palate. The CDC and FDA consider it contraindicated in the first trimester unless clearly needed. In the second and third trimesters, it is generally considered safe, but caution is advised near term due to potential neonatal accumulation.
Excreted in breast milk; M/P ratio ~1.0; American Academy of Pediatrics considers compatible; delay breastfeeding 12-24h after IV dose.
Metronidazole is excreted into breast milk with milk-to-plasma ratio of approximately 0.6-1.0. Peak milk concentrations occur 2-4 hours after dose. The American Academy of Pediatrics considers it compatible with breastfeeding, but some sources advise discarding milk for 12-24 hours after a single high dose (2 g) to reduce infant exposure. For standard dosing, benefits likely outweigh risks.
No dose adjustment required for topical METROGEL; systemic absorption negligible.
Pharmacokinetic changes in pregnancy (increased volume of distribution, enhanced hepatic clearance) may reduce serum concentrations of metronidazole, but the clinical significance is unclear. No dose adjustment is routinely recommended; however, for serious infections, therapeutic drug monitoring may be considered. Standard dosing (e.g., 500 mg IV every 8 hours) is typically used.
Metro Gel (metronidazole topical gel) is first-line for rosacea papules/pustules; avoid use in ocular rosacea as it can worsen symptoms. It is not effective for erythematotelangiectatic rosacea. For bacterial vaginosis, oral or intravaginal metronidazole is preferred; Metro Gel is not FDA-approved for vaginosis. In acne, it is less effective than topical antibiotics like clindamycin. Warn patients about rare metallic taste if gel is applied near lips.
Metronidazole IV exhibits excellent bioavailability; oral and IV dosing are equivalent. Avoid ethanol-containing medications or diet due to disulfiram-like reaction. Monitor for peripheral neuropathy with prolonged use. Adjust dose in severe hepatic impairment (Child-Pugh C).
Apply a thin layer to affected areas once or twice daily as directed; avoid contact with eyes, mouth, and mucous membranes.,Do not use cosmetics or other skin products on treated areas unless approved by your doctor.,Avoid sun exposure; use sunscreen and protective clothing as metronidazole may increase sensitivity to UV light.,Report any signs of allergic reaction (rash, itching, swelling) or worsening skin redness.,If accidental ingestion occurs, seek medical attention immediately; metronidazole can cause systemic side effects.,Do not use during pregnancy (especially first trimester) or while breastfeeding without consulting your healthcare provider.
Do not consume alcohol or products containing propylene glycol during treatment and for at least 48 hours after completion.,Report any numbness, tingling, or burning in hands or feet immediately.,Complete the full course as prescribed even if symptoms improve.,May cause metallic or bitter taste; this is temporary and harmless.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about METROGEL vs METRO I.V. IN PLASTIC CONTAINER, answered by our medical review team.
METROGEL is a Antibiotic (Nitroimidazole) that works by Metronidazole, after intracellular reduction, forms cytotoxic metabolites that disrupt bacterial DNA and inhibit nucleic acid synthesis. It also has anti-inflammatory and immunomodulatory effects in rosacea.. METRO I.V. IN PLASTIC CONTAINER is a Antibiotic (Nitroimidazole) that works by Metronidazole exerts its antibacterial and antiprotozoal effects by entering the microbial cell and undergoing reduction by intracellular electron transport proteins, forming reactive metabolites that interact with DNA, causing strand breakage and inhibition of nucleic acid synthesis.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between METROGEL and METRO I.V. IN PLASTIC CONTAINER depend on the specific clinical indication. These are both Antibiotic (Nitroimidazole) agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of METROGEL is: Topical application of 1% gel: Apply a thin layer to affected area twice daily; intravaginal 0.75% gel: one applicatorful (5 g) once daily at bedtime.. The standard adult dose of METRO I.V. IN PLASTIC CONTAINER is: IV: 500 mg every 6 h or 1 g every 12 h. For severe infections: 750 mg every 6 h. Max 4 g/day.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between METROGEL and METRO I.V. IN PLASTIC CONTAINER in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. METROGEL is classified as Category C. Metronidazole crosses the placenta. First trimester: avoid unless essential; second/third trimester: no increased risk of major malformations in large cohort studies; potential neu. METRO I.V. IN PLASTIC CONTAINER is classified as Category C. Metronidazole crosses the placenta. In the first trimester, data are conflicting but meta-analyses show no significant increase in major malformations; however, some studies sugges. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.